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Coding variants in RPL3L and MYZAP increase risk
of atrial ﬁbrillation
Rosa B. Thorolfsdottir et al.#
Most sequence variants identiﬁed hitherto in genome-wide association studies (GWAS) of
atrial ﬁbrillation are common, non-coding variants associated with risk through unknown
mechanisms. We performed a meta-analysis of GWAS of atrial ﬁbrillation among 29,502
cases and 767,760 controls from Iceland and the UK Biobank with follow-up in samples from
Norway and the US, focusing on low-frequency coding and splice variants aiming to identify
causal genes. We observe associations with one missense (OR= 1.20) and one splice-donor
variant (OR= 1.50) in RPL3L, the ﬁrst ribosomal gene implicated in atrial ﬁbrillation to our
knowledge. Analysis of 167 RNA samples from the right atrium reveals that the splice-donor
variant in RPL3L results in exon skipping. We also observe an association with a missense
variant in MYZAP (OR= 1.38), encoding a component of the intercalated discs of cardio-
myocytes. Both discoveries emphasize the close relationship between the mechanical and
electrical function of the heart.
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Atrial ﬁbrillation is the most common arrhythmia of clin-ical signiﬁcance with an estimated number of 33.5 millionindividuals diagnosed with atrial ﬁbrillation globally in
the year 20101. It is associated with increased mortality and
morbidity, particularly stroke and heart failure, and is responsible
for substantial health care costs1. Atrial ﬁbrillation is a complex
disease that is characterized by both mechanical and electrical
abnormalities of the atria that may be detected prior to diagnosis
of the arrhythmia itself. The role of atrial myopathy and ﬁbrosis
in the development of atrial ﬁbrillation is increasingly recognized
and it has been postulated that these processes may contribute to
cardioembolic stroke in the absence of arrhythmia2. Thus, iden-
tiﬁcation of the early stages of atrial myopathy may allow for
therapy to prevent progression to atrial remodeling, atrial ﬁbril-
lation, and stroke3.
Genome-wide association studies (GWAS), assessing primarily
common sequence variants, have yielded over 30 genetic loci that
associate with atrial ﬁbrillation4. Most of the associated variants
are non-coding and the causative genes remain unknown but the
closest genes reveal a polygenic process, implicating transcription
factors, cardiac ion channels, myocardial, and cytoskeletal pro-
teins in the pathogenesis of atrial ﬁbrillation. In the pre-GWAS
era, linkage mapping and candidate gene sequencing linked a
number of rare sequence variants to atrial ﬁbrillation, mostly in
single cases or familial atrial ﬁbrillation, including variants in
cardiac ion channel genes4. These variants explain a small pro-
portion of atrial ﬁbrillation cases, and for many, the genetic
evidence is not robust.
In the past few years, through GWAS based on whole-genome
sequencing, we have identiﬁed three low-frequency coding var-
iants that associate with atrial ﬁbrillation5–8. All three variants are
in structural genes, the myosin sarcomere genes MYH65 and
MYL46,7 and the cytoskeletal gene PLEC8. These ﬁndings support
the notion of an important relationship between myocardial
mechanical integrity and the development of arrhythmias.
Here, we continue our search for variants associated with atrial
ﬁbrillation to shed further light on the pathophysiology of this
common arrhythmia. We performed an atrial ﬁbrillation GWAS
using data from Iceland and the UK Biobank, focusing on rare
and low-frequency coding and splice variants, with follow-up of
the most signiﬁcant variants in samples from Norway and the US.
Results
Associations with coding variants in RPL3L and MYZAP. We
performed a meta-analysis on atrial ﬁbrillation including 14,710
cases and 373,897 controls from Iceland and 14,792 cases and
393,863 controls from the UK Biobank9, focusing on variants
annotated as having moderate or high impact on protein function
(including moderate: missense, in-frame indel, splice-region, and
high impact: splice-acceptor, splice-donor, frameshift, stop-
gained, and stop lost variants)10. To account for the expected
impact, we applied the signiﬁcance thresholds of P < 5.1 × 10−8
for moderate and P < 2.6 × 10−7 for high-impact variants11.
We found two novel genome-wide signiﬁcant atrial ﬁbrillation
associations in the gene RPL3L on chromosome 16, with the
missense variant p.Ala75Val (allele frequency 3.65% in Iceland, OR:
1.19, P= 3.4 × 10−12) and the splice-donor variant c.1167+1G>A
(allele frequency 0.61% in Iceland, OR: 1.52, P= 8.2 × 10−10). The
two RPL3L variants are not correlated (D’= 1, r2= 0.00024), and
when conditioned on each other, both associations with atrial
ﬁbrillation remained (Supplementary Table 1). To assess the
relationship between RPL3L and atrial ﬁbrillation further, we tested
all 15 low-frequency coding variants in the gene for association with
atrial ﬁbrillation after conditioning on p.Ala75Val and c.1167
+1G>A (signiﬁcance threshold= 0.05/15= 0.0033, Supplementary
Table 2). One variant associated with atrial ﬁbrillation with a P-
value below this threshold but the association was not genome-wide
signiﬁcant in the meta-analysis. The RPL3L gene encodes a
ribosomal protein (ribosomal protein like 3L) that is primarily
expressed in skeletal muscle and heart unlike most ribosomal
proteins, that are ubiquitously expressed12.
We also observed a suggestive association with the missense
variant p.Gln254Pro in the gene MYZAP on chromosome 15
(allele frequency 1.08% in Iceland, OR: 1.36, P= 7.8 × 10−8)
(Table 1). No other coding variant in MYZAP associates
independently with atrial ﬁbrillation (Supplementary Table 3).
MYZAP encodes myozap, myocardial zonula adherens protein,
primarily expressed in the heart in man and its homolog in the
mouse has been localized to the intercalated discs13.
To further assess these associations, we tested the three
sequence variants in four additional sample sets of 9204 cases and
76,161 controls combined, from the Nord-Trøndelag Health
Study (HUNT), the Further Cardiovascular Outcomes Research
with PCSK9 Inhibition in Subjects with Elevated Risk (FOURIER)
trial, the Vanderbilt atrial ﬁbrillation Registry, and the Tromsø
Study. Joint analysis of all data sets yielded genome-wide
signiﬁcant association with atrial ﬁbrillation of all three variants,
RPL3L Ala75Val (OR: 1.20, P= 1.7 × 10−14), RPL3L
c.1167+1G>A (OR: 1.50, P= 5.0 × 10−10), and MYZAP p.
Gln254Pro (OR: 1.38, P= 3.3 × 10−10) (Table 1).
Three other moderate or high-impact coding variants in the
genes MYH6, PLEC, and MYL4 (recessive model), previously
reported by us, were genome-wide signiﬁcantly associated with
atrial ﬁbrillation in this data set5–8.
The p.Ala75Val in RPL3L associates with electrocardiogram
measures. We have previously demonstrated that the effects of
reported atrial ﬁbrillation variants on ECG traits measured in
sinus rhythm range from none to extensive and there is no clear
relationship between effects on atrial ﬁbrillation and effects on
ECG measures8. For example, a sequence variant associated with
atrial ﬁbrillation in the sodium channel gene SCN10A has
extensive and strong effects on ECG measures but a relatively
small atrial ﬁbrillation effect compared to the most signiﬁcant
common atrial ﬁbrillation variant near PITX2 that has minimal
effect on ECG measurements (Fig. 1). Figure 1 shows the effects
of the RPL3L and MYZAP variants on ECG traits compared to
the effects of 31 published atrial ﬁbrillation variants. For the
analysis we used 289,297 sinus rhythm ECGs from 62,974 indi-
viduals not diagnosed with atrial ﬁbrillation and tested all var-
iants for association with 122 ECG variables, some of which are
correlated (Supplementary Table 4 and Supplementary Data 1).
We used the Benjamini–Hochberg false discovery rate (FDR)
procedure controlling the FDR at 0.05 at each marker to account
for multiple testing. The RPL3L missense variant p.Ala75Val
associates with measures of atrial conduction during sinus
rhythm, both P wave amplitude and area, and with QRS duration.
Neither of the other variants in RPL3L and MYZAP associated
with ECG traits in sinus rhythm. When testing for association
with ECG traits using all ECGs irrespective of rhythm and history
of atrial ﬁbrillation, p.Ala75Val in RPL3L associates more sig-
niﬁcantly with ECG measurements and p.Gln254Pro in MYZAP
associates with various P wave indices, R amplitude, and T wave
indices (Supplementary Fig. 1).
The p.Gln254Pro in MYZAP associates with sick sinus syn-
drome. Variants that associate with risk of atrial ﬁbrillation also
tend to associate with the related atrial arrhythmia sick sinus
syndrome (SSS) and commonly with effects that are proportional
to the atrial ﬁbrillation effects8. One notable exception is the
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missense mutation in MYH6 that we originally discovered
through its association with high risk of SSS and confers a sub-
stantially greater risk of SSS than predicted from its effect on
atrial ﬁbrillation risk5. We tested the three new atrial ﬁbrillation
variants in 3568 SSS cases and 346,025 controls from Iceland
and 403 cases and 403,181 controls from the UK Biobank9. In the
joint analysis, p.Gln254Pro in MYZAP associates with SSS
(OR: 1.65, 95% CI: 1.33–2.05, P= 5.0 × 10−6) (Supplementary
Table 5).
To gain a better understanding of the new atrial ﬁbrillation
variants, we tested them for association with other phenotypes in
deCODE´s genotype/phenotype database under both additive and
recessive models but found no other associations passing
Bonferroni correction. Association results for available relevant
phenotypes including risk factors of atrial ﬁbrillation are listed in
Supplementary Tables 6 and 7. Since mutations in ribosomal
genes are commonly associated with bone marrow failure, we
speciﬁcally queried the relationship between the RPL3L variants
and blood cells and found no associations. Similarly, since
mutations in intercalated disc genes, albeit not MYZAP, have
been associated with cardiomyopathies in man14 we assessed the
link between the MYZAP variant and cardiomyopathies in our
database, but found none.
The splice-donor variant in RPL3L causes exon skipping. We
obtained RNA samples from cardiac atria of 167 Icelanders and
used them to assess the effect of the splice-donor variant c.1167
+1G>A in RPL3L. Two of the 167 individuals carry this variant.
Non-carriers only produce the primary RPL3L isoform, but both
carriers also produce an alternative isoform that skips exon 9 (P
= 0.0052, Fig. 2a). We also found that carriers express the two
isoforms in approximately equal abundance. Exon 9 is the second
to last exon in RPL3L and is 120 base pairs long, and therefore its
deletion is in-frame (Fig. 2b).
Discussion
By performing a meta-analysis of atrial ﬁbrillation using samples
from deCODE and the UK biobank, focusing on rare and low-
frequency coding and splice variants, with follow up in four
sample sets from Norway and the US, we discovered three new
atrial ﬁbrillation variants in two genes, two in the ribosomal gene
RPL3L and one in MYZAP that encodes a component of the
cardiac intercalated discs. Risk of atrial ﬁbrillation has not been
associated with a ribosomal gene before.
The eukaryotic ribosome, composed of four different ribosomal
RNAs and ~80 ribosomal proteins, is a complex cellular machine
that translates messenger RNA into protein15. Only a few rare
inherited diseases have been speciﬁcally linked to mutations in
genes encoding ribosomal proteins. They include
Diamond–Blackfan anemia and Shwachman–Diamond syn-
drome that are characterized by a distinct set of clinical features,
including bone marrow failure and/or developmental abnormal-
ities16. The ribosome has generally been considered to function in
a housekeeping capacity but recent studies have revealed that
ribosome activity may be regulated in a cell-speciﬁc manner, for
example through changes in the protein composition of the
ribosome17,18. One example is the RPL3L with expression
restricted to skeletal muscle and the heart12. Ribosomes con-
taining RPL3L instead of its ubiquitously expressed homolog,
RPL3, have altered translational activity and it has been postu-
lated that RPL3L may be a negative regulator of muscle growth19.
The RPL3L missense variant associating with atrial ﬁbrillation
is p.Ala75Val, and Ala75 is highly conserved in both RPL3L and
RPL3 over a range of species (PROVEAN impact prediction
scores <−2.520) (Supplementary Table 8). Sequencing of RNAT
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samples from cardiac atria including from carriers of the splice-
donor variant, c.1167+1G>A, demonstrated that the variant leads
to skipping of RPL3L exon 9, the second to the last exon that
encodes amino acid residues 350 to 389. These residues are 75%
identical to the corresponding RPL3 residues. In yeast it has been
shown that amino acids 373–380 in RPL3, corresponding to
amino acids 382–389 in human RPL3L, form a part of the contact
site of the ribosomes with the signal recognition particle that
targets ribosomes to the endoplasmic reticulum membrane21.
Based on functional similarities between RPL3 and RPL3L it is
therefore possible that c.1167+1G>A disrupts engagement of
RPL3L containing ribosomes with the endoplasmic reticulum and
thus reducing ribosomal function. Since both RPL3L variants
increase the risk of atrial ﬁbrillation it could be predicted, based
on the suggested effect of the splice-donor variant, that the var-
iants are loss of, rather than gain of, function. The association of
atrial ﬁbrillation with a gene expressed in the atria that is involved
with regulation of muscle growth is in line with the increasingly
recognized tight link between mechanical myocardial integrity
and the electrical function of the heart.
The MYZAP gene was recently discovered by Seeger et al. in an
effort to ﬁnd new components of the intercalated discs13, a highly
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Fig. 1 Heatmap showing the effects of atrial ﬁbrillation variants on ECG traits in sinus rhythm ECGs, excluding atrial ﬁbrillation cases. See Thorolfsdottir
et al8. ECG measurements were available for 62,974 individuals without atrial ﬁbrillation. Each column shows the estimated effect of the risk allele of an
atrial ﬁbrillation variant on various ECG traits. The effect of each variant, annotated with the corresponding gene name, is scaled with the log10-atrial
ﬁbrillation odds ratio. Red color represents a positive effect on the ECG variable and blue color a negative effect. The effect is shown only for signiﬁcant
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ARTICLE COMMUNICATIONS BIOLOGY | DOI: 10.1038/s42003-018-0068-9
4 COMMUNICATIONS BIOLOGY |  (2018) 1:68 | DOI: 10.1038/s42003-018-0068-9 |www.nature.com/commsbio
specialized cell–cell contact structure that enables mechanical, elec-
trical and chemical communication between cardiomyocytes. Human
Myozap mRNA is primarily expressed in the heart and in the mouse
the protein was predominantly found at intercalated discs and sar-
comeric Z-discs13. In vitro functional studies revealed a role in car-
diac signal transduction as Myozap promotes serum response factor
signaling to the nucleus13. A knockdown of the Myozap ortholog in
zebraﬁsh and cardiac overexpression of Myozap in the mouse both
resulted in cardiomyopathy13,22, suggesting an important role of the
protein in maintaining cardiac integrity and function.
According to PROVEAN20, Gln254 is conserved and the var-
iant is predicted to be deleterious (Supplementary Table 8). The
variant is located at the edge of the Myozap protein region
associated with both activation of serum response factor-
dependent transcription and actin colocalization (amino acids
91–250), and could therefore potentially affect either one or both
of these protein functions13. An introduction of proline, a con-
formationally constrained amino acid, can lead to perturbations
in local folding and therefore might interrupt the function of
adjacent domains.
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transcripts. A total of 167 samples, all from the right atrium, where included in the analysis. Two of those came from carriers of c.1167+1G>A. The ﬁgure
demonstrates that only the two carriers have the novel isoform with skipping of exon 9. Their exon skipping proportion is ~0.5 while it is zero in non-
carriers. b A schematic illustration of the splicing of RPL3L among carriers and non-carriers of c.1167+G>A. The variant is in a splice-donor site by the
second last exon and results in exon skipping. The skipped exon is 120 base pairs and therefore its deletion is in-frame
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Mutations in intercalated disc genes cause cardiomyopathies,
in particular arrhythmogenic right ventricular cardiomyopathy,
characterized by a notable risk of both atrial ﬁbrillation and
ventricular arrhythmias, and one of the leading causes of sudden
cardiac death in young people and athletes23. Interestingly, con-
duction abnormalities and arrhythmias in arrhythmogenic right
ventricular cardiomyopathy are commonly encountered before
the appearance of structural defects14. Atrial ﬁbrillation variants
have also been identiﬁed in and close to genes encoding com-
ponents of intercalated discs4, and the atrial ﬁbrillation-associated
gene PITX2 has been shown to directly regulate intercalated disc
genes24. P.Gln254Pro does not associate with cardiomyopathies,
ventricular arrhythmias, or sudden cardiac death in our data,
suggesting that it only affects the atria but we may lack power to
identify a ventricular effect.
Like p.Gln254Pro in MYZAP, the three low-frequency mis-
sense and frameshift variants we have previously reported to
increase the risk of atrial ﬁbrillation, in MYH6, MYL4, and PLEC,
also increase the risk of SSS8. LikeMYZAP, all three genes encode
structural components of the cardiomyocyte. In particular, PLEC
encodes a multidomain cytoskeletal linking protein which, among
other functions, connects with elements of the intercalated disc
and has a role in maintaining its integrity25,26.
In summary, we report the association of three low-frequency
coding variants in RPL3L and MYZAP with increased risk of
atrial ﬁbrillation. Using RNA samples from cardiac tissue we
show that a splice-donor variant in RPL3L causes exon skipping.
These results add to previous discoveries of three low-frequency
coding variants in structural genes associating with atrial ﬁbril-
lation and highlight the intricate connection between myocardial
structure and arrhythmogenesis. The association of a missense
variant in MYZAP with atrial ﬁbrillation and SSS emphasizes the
role of the intercalated discs in maintaining normal cardiac
rhythm. The fact that a coding variant in a ribosomal protein
speciﬁcally expressed in skeletal muscle and the heart increases
risk of atrial ﬁbrillation is in line with the novel concept of
ribosome specialization in muscle and underscores the impor-
tance of this specialization for normal function of the heart.
GWAS have linked a number of common variants with risk of
atrial ﬁbrillation but emerging discoveries of low-frequency
coding variants associating with atrial ﬁbrillation continue to
shed new light on the pathogenesis of the disease.
Methods
The study complies with the Declaration of Helsinki.
Icelandic atrial ﬁbrillation study population. The Icelandic atrial ﬁbrillation
sample consisted of 15,552 Icelanders diagnosed with atrial ﬁbrillation (Interna-
tional Classiﬁcation of Diseases (ICD) 10 code I.48 and ICD 9 code 427.3)
according to electronic medical records at Landspitali, The National University
Hospital, in Reykjavik, Iceland, and Akureyri Hospital, the two largest hospitals in
Iceland, between 1987 and 2017. In total, 14,710 out of the 15,552 cases had
genotypes and were included in the analysis. Controls were 373,897 Icelanders
recruited through different genetic research projects at deCODE genetics. All
participating subjects who donated blood signed informed consent. Personal
identities of the participants and biological samples were encrypted by a third party
system. The study was approved by the Icelandic Data Protection Authority and
the National Bioethics Committee of Iceland (no. VSNb2015030021).
UK Biobank atrial ﬁbrillation study population. The UK Biobank project is a
large prospective cohort study of ~500,000 individuals from across UK, aged
between 40 and 69 at recruitment. The study has collected extensive phenotypic
and genotypic information on its participants, including ICD coded diagnoses from
inpatient and out-patient hospital episodes9. The atrial ﬁbrillation population from
UK Biobank consisted of 14,792 cases and 393,863 controls, all individuals of
European ancestry recruited between 2006 and 20109. Atrial ﬁbrillation was
ascertained based on ICD diagnoses. These are primary or secondary ICD-9 or
ICD-10 diagnoses codes a participant has had recorded across all their episodes in
hospital. Self-reported diagnoses were excluded from our analysis. Further details
on the recruitment and variables collected in the UK Biobank study can be found
in previous publications9,27.
The Vanderbilt Atrial Fibrillation Registry. We genotyped novel atrial ﬁbrillation
variants in an atrial ﬁbrillation sample set (759 cases and 759 controls) from the
Vanderbilt Atrial Fibrillation Registry, a clinical and genetic registry at the Van-
derbilt University Medical Center in Nashville, Tennessee. At enrollment into the
registry, a detailed medical and drug history was obtained from all patients and
patients were also asked to complete a symptom questionnaire. Patients with
history of atrial ﬁbrillation only associated with cardiac surgery were excluded from
this study. Written informed consent was obtained from all patients under a
protocol approved by the Vanderbilt University Institutional Review Board.
FOURIER replication cohort. We also followed-up novel atrial ﬁbrillation variants
in an atrial ﬁbrillation sample set originating from the Further Cardiovascular
Outcomes Research with PCSK9 Inhibition in Subjects with Elevated Risk
(FOURIER) trial (1238 atrial ﬁbrillation cases and 11,562 controls). FOURIER is a
randomized placebo-controlled, double-blind, parallel-group, multinational trial
testing the hypothesis that adding the drug evolocumab to statin therapy will
reduce the incidence of major adverse cardiovascular events in patients with
clinically evident cardiovascular disease (CVD). The whole study group consisted
of 27,564 patients recruited at 1242 cities in 49 countries from 2013 to 2015.
Eligible patients were between 40 and 85 years of age and had clinically evident
atherosclerotic CVD. The design of the trial has been described in detail else-
where28,29. A subset of over 12,000 participants of European descent from the
FOURIER trial have been genotyped by us by whole-exome sequencing, chip-
typing, and imputation. Detailed phenotypic information was gathered on all
FOURIER study participants, including atrial ﬁbrillation disease status. The Fourier
atrial ﬁbrillation sample set consists of 1238 cases and 11,562 controls of European
descent, excluding all Icelandic participants.
Norwegian atrial ﬁbrillation study population from the Tromsø Study. The
Tromsø Study is a population-based prospective study with repeated health surveys
in the municipality of Tromsø, Norway30. So far, more than 40,000 individuals
have been examined.The population is being followed-up on an individual level
with registration and validation of diseases and death and an endpoint registry has
been established for CVD. Discharge diagnosis lists of CVD have been retrieved
from the University Hospital of North Norway in Tromsø, and medical records for
all individuals with a CV discharge diagnosis (including visits to out-patient clinics,
out of hospital journals, autopsy records, and death certiﬁcates) have been
reviewed. Atrial ﬁbrillation has been registered based on ICD-9 and ICD-10 codes
since 1986 as part of the ongoing CV endpoint registration in the Tromsø Study.
People with postoperative atrial ﬁbrillation only (≤28 days after the procedure) are
registered, but are not included as cases. For the current project, one sex-matched
and age-matched control for each case of atrial ﬁbrillation from was drawn from
the population-based Tromsø 4 survey. Participants in the Tromsø Study gave
informed, written consent. The study was approved by the Regional Committee for
Medical Research Ethics. The atrial ﬁbrillation sample set consists of 714 cases and
698 controls.
The Nord-Trøndelag Health Study. The Nord-Trøndelag Health Study (HUNT)
is a population-based health survey conducted in the county of Nord-Trøndelag,
Norway. Individuals were included at three different time points during ~20 years
(HUNT1 (1984–1986), HUNT2 (1995–1997), and HUNT3 (2006–2008))31. At
each time point, the entire adult population (≥20 years) was invited to participate
by completing questionnaires, attending clinical examinations, and interviews.
Participation rates have generally been high: 89.4% (n= 77,212), 69.5% (n=
65,237), and 54.1% (n= 50,807) in HUNT1, HUNT2, and HUNT3, respectively31.
Taken together, the health studies included information from over 120,000 dif-
ferent individuals from Nord-Trøndelag. Biological samples including DNA have
been collected for ~70,000 participants. Atrial ﬁbrillation was deﬁned based on
ICD-10 codes collected from local hospitals and out-patient clinics between 1999
and 2016. Cases (6493) were deﬁned as individual with one or more ICD-9 or ICD-
10 codes speciﬁc for atrial ﬁbrillation (“I48” or “427.3”) whereas controls (63,142)
were all individuals without a code speciﬁc for atrial ﬁbrillation.
Secondary phenotypes. Novel atrial ﬁbrillation variants were tested for associa-
tion with other phenotypes in the deCODE genetics phenotype database which
contains extensive medical information on various diseases and other traits. The
pacemaker population sample set includes 3578 individuals who received a pace-
maker implantation (NCSP surgical codes FPE and FPF) at LUH between 1997 and
2015. The SSS sample set includes 3578 individuals who received the diagnosis of
SSS (ICD-10 code I49.5, ICD 9 code 427.8) at LUH in Reykjavik between 1987 and
2015. Ischemic stroke cases were identiﬁed from a registry of individuals diagnosed
with ischemic stroke or transient ischemic attack (TIA) at LUH during the years
1993 to 2014 (n= 5626). The ischemic stroke or TIA diagnoses were based on
standard WHO criteria and imaging evidence (either CT or MRI), and were
clinically conﬁrmed by neurologists. A total of 1369 individuals with ischemic
stroke were classiﬁed as having cardioembolic stroke based on a neurologist review
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of medical records and classiﬁcation according to the Trial of Org 10172 in Acute
Stroke Treatment (TOAST)32. The controls used in the various case–control
analyses of this study consisted of disease-free controls randomly drawn from the
Icelandic genealogical database and individuals from other genetic studies at
deCODE. We also assessed the association of novel atrial ﬁbrillation variants with
SSS among 403 cases and 403,181 controls in the UK Biobank.
Electrocardiogram data. Electrocardiograms (ECGs) obtained in Landspitali, The
National University Hospital, the largest and only tertiary care hospital in Iceland,
have been digitally stored since 1998. We have analysed 434,000 ECGs from 88,217
individuals obtained between 1998 and 2015. To assess the effect of atrial ﬁbril-
lation variants on ECG traits, and thus cardiac electrical function, in the absence of
atrial ﬁbrillation, we excluded ECGs from individuals with atrial ﬁbrillation and
pacemakers and used 289,297 sinus rhythm (heart rate 50–100 beats per min)
ECGs of 62,974 individuals for the primary analysis. The ECGs were digitally
recorded with the Philips PageWriter Trim III, PageWriter 200, Philips Page
Writer 50, and Phillips Page Writer 70 cardiographs and stored in the Philips
TraceMasterVue ECG Management System. These were ECGs obtained in all
hospital departments, from both in patients and outpatients. Digitally measured
ECG waveforms and parameters were extracted from the database for analysis. The
Philips PageWriter Trim III QT interval measurement algorithm has been pre-
viously described and shown to fulﬁll industrial ECG measurement accuracy
standards33. The Philips PR interval and QRS complex measurements have been
shown to fulﬁll industrial accuracy standards34.
Whole-genome sequencing, variant calling, and imputation in Iceland. In
Iceland, the study is based on whole-genome sequence data from the whole blood
of 15,220 Icelanders participating in various disease projects at deCODE genetics.
In addition, 151,677 Icelanders have been genotyped using Illumina SNP chips and
genotype probabilities for untyped relatives has been calculated based on Icelandic
genealogy. The sequencing was done using Illumina standard TruSeq methodology
to a mean depth of 35 (SD 8). Autosomal SNPs and INDEL’s were identiﬁed using
the Genome Analysis Toolkit version 3.4.035. Variants that did not pass quality
control were excluded from the analysis according to GATK best practices7.
Information about haplotype sharing was used to improve variant genotyping,
taking advantage of the fact that all sequenced individuals had also been chip-typed
and long-range phased36.
The informativeness of genotype imputation (imputation information) was
estimated by the ratio of the variance of imputed expected allele counts and the
variance of the actual allele counts:
VarðEðθjchip dataÞÞ
VarðθÞ
where θ is the allele count. Here, Var(E(θ/chip data)) is estimated by the observed
variance in the imputed expected counts and Var(θ) was estimated by p(1− p),
where p is the allele frequency.
Variants were annotated using Ensembl release 80 and Variant Effect Predictor
(VEP) version 2.810. A total of 32.5 million variants passed the quality threshold
and were imputed into 151,677 Icelanders who had been genotyped using Illumina
chips.
To account for inﬂation in test statistics due to cryptic relatedness and
stratiﬁcation, we applied the method of LD score regression37. With a set of 1.1M
variants we regressed the χ2 statistics from our GWAS scan against LD score and
used the intercept as a correction factor. The LD scores were downloaded from a
LD score database (ftp://atguftp.mgh.harvard.edu/brendan/
1k_eur_r2_hm3snps_se_weights.RDS; accessed 23.06.2015). The estimated
correction factor for atrial ﬁbrillation based on LD score regression was 1.39 for the
additive model in the Icelandic sample and 1.04 in UK Biobank.
Genotyping in the UK biobank data. In the UK Biobank, genotyping was per-
formed using a custom-made Affymetrix chip, UK BiLEVE Axiom38, in the ﬁrst
50,000 participants, and with Affymetrix UK Biobank Axiom array in the
remaining participants39; 95% of the signals are on both chips. Imputation was
performed by Wellcome Trust Centre for Human Genetics using a combination of
1000Genomes phase 340, UK10K41, and Haplotype Reference Consortium (HRC)
reference panels42, for up to 92,693,895 SNPs43.
Single-variant genotyping. For genotyping of single variants in atrial ﬁbrillation
sample sets from the Vanderbilt registry, FOURIER trial, and Norway, we used the
Centaurus (Nanogen) or KASP platforms.
Statistical analysis. We performed a meta-analysis on 14,710 atrial ﬁbrillation
cases and 373,897 controls from Iceland and 14,792 atrial ﬁbrillation cases and
393,868 controls from the UK Biobank. We used logistic regression to test for
association between SNPs and atrial ﬁbrillation and other phenotypes in the Ice-
landic study, treating phenotype status as the response and allele count as a cov-
ariate. We used allele counts from genotyping or integrated over possible genotype
counts based on imputation. Other available individual characteristics that
correlate with phenotype status were also included in the model as nuisance
variables. In Iceland these covariates were: sex, county of birth, current age, or age
at death (ﬁrst and second order terms included), blood sample availability for the
individual and an indicator function for the overlap of the lifetime of the individual
with the time span of phenotype collection. In the UK biobank study 40 principal
components were used to adjust for population stratiﬁcation and age and sex were
included as covariates in the logistic regression model. Only white British indivi-
duals were included in the study. For the meta-analysis we used a ﬁxed-effects
inverse variance method44 based on effect estimates and standard errors from the
Icelandic and the UK Biobank study. Only sequence variants from the Haplotype
Reference Consortium panel (HRC)42 were included in the meta-analysis and
variants from deCODE and the UK Biobank imputation were matched on position
and alleles. Standard errors were calculated in the following way:
For a P-value smaller than 1 we calculate the standard error as follows:
P ¼ 2Φ zð Þ ¼ 2Φ β
σ
 
:
Solving for σ gives
σ ¼ β
Φ1 P2
 
If P= 1, then Φ1 P2
  ¼ 0 and the above method breaks down. In this case we use
data from other markers to estimate the relationship between allele frequency (f)
and imputation information (I) and σ as follows:
Var βð Þ ¼ σ2 / 1
N
f ð1 f Þ / 1
I
f ð1 f Þ
Sample size (N) is proportional to imputation information (I) if we are always
basing the analysis on the same set of individuals. Therefore, if we ﬁt the following
linear model:
log σ2
  ¼ γ1 þ γI logðIÞ þ γf logðf 1 fð ÞÞ
for a subset of 100,000 markers spread over the genome with MAF ranging close to
uniformly between 0.1 and 50% and info between 0.9 and 1 and pick the subset of
markers with P < 0.9 then we can predict σ for a marker with P close to 1.
We corrected the threshold for genome-wide signiﬁcance for multiple testing
with a weighted Bonferroni adjustment using as weights the enrichment of variant
classes with predicted functional impact among association signals estimated from
the Icelandic data11.
With 32,463,443 sequence variants in the Icelandic data the weights given in
Sveinbjornsson et. al. were rescaled to control the family-wise error rate. This
yielded signiﬁcance thresholds of 2.6 × 10−7 for high-impact variants (N= 8464)
and 5.1 × 10−8 for moderate-impact variants (N= 149,983).
Conditional analysis of the region around novel atrial ﬁbrillation variants, was
performed by adding the top variant or variants as a covariate while testing every
SNP in the region for association with atrial ﬁbrillation in the Icelandic data.
We tested atrial ﬁbrillation variants for association with 122 ECG
measurements using linear regression, treating the ECG measurement as the
response and the genotype as the covariate. Following the procedures described in
Thorolfsdottir et al.8, ECG measurements were adjusted for sex, year of birth, and
age at measurement and were subsequently standardized to have a normal
distribution. For individuals with multiple ECG measurements, the mean
standardized value was used. We assume that the quantitative measurements follow
a normal distribution with a mean that depends linearly on the expected allele at
the variant and a variance-covariance matrix proportional to the kinship matrix45.
The Benjamini–Hochberg FDR procedure controlling the FDR at 0.05 at each
marker was used to account for multiple testing.
Expression analysis in cardiac tissue. RNA sequencing was performed on
samples from cardiac right atrium of 167 Icelanders (see Supplementary Table 9,
for subject characteristics). The samples were obtained during cardiothoracic
surgery at Landspitali, The National University Hospital, in Reykjavik, Iceland. In
the case of the splice-donor variant in RPL3L (c.1167+1G>A), the RNA samples
from cardiac atria were used to identify a novel isoform and quantify expression at
the transcript level. RNA sequencing libraries were inspected for sequencing and
alignment integrity using parameters retrieved from RNA-SeQC46, Picard Col-
lectRnaSeqMetrics (http://broadinstitute.github.io/picard/), and FastQC (http://
www.bioinformatics.babraham.ac.uk/projects/fastqc). Genotype concordance was
determined by comparing imputed genotypes to those derived from RNA-seq.
Genome alignments were found using STAR47 aligning to GRCh38 with ensemble
v8748 gene annotations. Alignments of RNA-seq reads of carriers of the variant
contained several reads that spliced over exon 9 in transcript ENST00000268661 of
RPL3L. Neither of the two other transcripts of RPL3L showed any expression in all
samples (See Supplementary Fig. 2). To assess quantitatively the effect of the
variant on the isoform usage we created the transcript sequence for the novel
isoform, added it to the ensemble v87 transcriptome, and re-quantiﬁed all samples
using kallisto49 and the modiﬁed transcriptome. The expression of the annotated
and novel transcript was corrected w.r.t. the size factor computed from the gene
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expression analysis. Finally the proportion of novel isoform usage was computed by
dividing the estimated expression of the novel isoform with the sum of the
expression of both isoforms. Due to the small number of carriers, two samples out
of 167, we opted for a conservative test for computing the signiﬁcance of the
observed event, that the carriers have a ratio of 50% vs near 0% for non-carriers.
The test used was the two-sided Mann–Whitney U test, which only takes the
relative ranks of the samples into account and not the underlying values. The P-
value computed was P= 0.0052, the lowest possible P-value that can be obtained
using this statistical test with n1= 165 and n2= 2.
Data availability. The Icelandic population WGS data has been deposited at the
European Variant Archive under accession code PRJEB8636. The authors declare
that the data supporting the ﬁndings of this study are available within the article, its
Supplementary Data ﬁles and upon request.
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